How to Sell a Private Medical Clinic — Conclave Partners

A private clinic is three assets stacked on top of each other: an authorisation to provide medical care, a group of doctors whose individual reputations bring patients through the door, and a patient base that belongs, legally, to neither. Each of the three transfers differently, and some of them may not transfer at all.

That is why clinic transactions behave unlike other healthcare deals. The commercial negotiation is often the easy part. The difficult questions are whether the buyer is legally permitted to own the business, whether the licence survives the change of ownership, and what happens to the referral flow when the doctor whose name is on the door stops answering the phone.

This article sets out who may legally buy, how authorisations behave in a sale, how buyers price the medical team, and what an owner should fix in the year before going to market.

In several European jurisdictions the buyer universe for a medical practice is limited by statute before it is limited by price, and the restrictions have tightened rather than loosened.

Germany is the clearest example. A Medizinisches Versorgungszentrum — the standard vehicle for outpatient medical care — may only be founded by a defined set of parties under Section 95(1a) SGB V: authorised physicians, hospitals, and certain non-profit bodies among them. There is no free choice of shareholder. The permitted legal forms are similarly limited, to a partnership, a registered cooperative, a GmbH or a public-law entity.

The position on outside capital was reinforced at European level. In a decision of 19 December 2024 the Court of Justice confirmed the prohibition on third-party participation in professional practice associations of the liberal professions. The practical effect in Germany is that a financial investor cannot hold shares in a medical care centre directly. Investment is possible only indirectly — most commonly by acquiring a hospital that in turn holds the shares in the centre.

Comparable logic appears in other jurisdictions, where practice ownership is reserved to registered practitioners or to entities in which practitioners hold defined control. The details differ; the pattern does not.

For a seller, three consequences follow. The pool of buyers is smaller than the accounts suggest and must be identified by legal eligibility before commercial fit. The structure is frequently determined by regulation rather than preference — a buyer may have to acquire through a permitted vehicle, which lengthens the process. And a buyer who has not solved this before approaching you is not a buyer. At Conclave Partners the first work on a clinic mandate is establishing which acquirers can lawfully complete, because a process run to an ineligible bidder wastes months and leaks confidentiality for nothing.

Owners tend to speak of "the licence" as though it were an item on the balance sheet. In most European systems it is closer to a permission granted to a specific operator, at a specific address, for specified activities, and it responds to a change of ownership.

Three distinctions matter.

The first is between the facility authorisation and the individual practitioner registration. The clinic's right to operate and each doctor's right to practise are separate permissions from separate authorities, and a transaction can satisfy one while breaching the other.

The second is between a share sale and an asset sale. Where the operating entity keeps its authorisation, a share sale may allow continuity subject to notification. In an asset sale the authorisation frequently does not travel with the assets and must be applied for afresh, which can mean an interruption in trading — commercially fatal in a business whose patients can go elsewhere in a week.

The third is any contract with a public payer or insurer. Panel places, reimbursement contracts and network memberships often have their own change-of-control procedures, and they may be the most valuable single item in the transaction. They also may not be transferable at all.

The practical step is to obtain, before launch, a written answer from the relevant authority or from specialist counsel on what happens to each permission on a change of ownership, and on what timeline. Sellers who bring that answer to the process shorten it by months.

Once the authorisations are understood, the buyer moves to the people, and applies reasoning familiar from any professional services business — with a clinical overlay.

Buyers examine who generates the activity. If one consultant produces the majority of the clinic's revenue, the clinic has a key person problem regardless of how good the facility is. They examine how patients arrive: self-referral driven by a named doctor's reputation is personal and may leave; referral from general practitioners, insurers or hospitals to the clinic as an institution is more likely to stay.

They examine contractual position. Are the doctors employed, self-employed with practising privileges, or partners? Notice periods, non-compete and non-solicitation clauses, and the enforceability of those clauses in the relevant jurisdiction all bear directly on price, because a departing doctor who can open across the street next month is a different risk from one who cannot.

They also examine coverage: whether the clinic can continue to deliver its full service list if any one clinician leaves, and whether locum or sessional cover is available in that specialty and geography.

The remedy is the same as in other people businesses but harder here, because clinical reputation is genuinely personal. What can be transferred is the institutional layer around it: shared protocols, a clinic-branded patient pathway, multi-clinician cover for each service line, and referral relationships held by the clinic rather than by an individual. In our experience at Conclave Partners, the clinics that sell best are those where a patient chooses the clinic and is then allocated a doctor, rather than choosing a doctor who happens to work at a clinic.

Ranges vary widely by specialty, payer mix and scale, and published benchmarks should be treated as orientation rather than valuation. What is more consistent, and more useful to understand in advance, is the shape of the consideration.

Before the multiple, buyers look at where the money comes from. Self-pay income is priced on demand and pricing power, and is exposed to the economic cycle. Private insurance income is more stable but depends on network membership and negotiated tariffs that the insurer can revise. Public or statutory income is the most predictable and the least controllable: volumes and prices are set administratively, and a tariff change can move the whole earnings base without anything happening inside the clinic. A payer mix presented clearly, with the contractual terms behind each stream and their renewal dates, tells a buyer more about the durability of the earnings than any growth narrative.

Healthcare transactions in the current market carry more structure than they did a few years ago. Regulatory and political scrutiny of investor ownership in medical practice has intensified, and buyers have responded by shifting risk back to sellers: larger rollover equity — commonly a fifth to two fifths of the consideration — longer earn-outs, escrows held specifically against regulatory and compliance risk, and tighter management incentive arrangements.

None of that is arbitrary. Each element maps to one of the risks above: rollover keeps the selling clinicians invested, the earn-out protects against referral loss, and the regulatory escrow covers the possibility that an authorisation, a reimbursement contract or a historic billing practice turns out to be defective. A seller who understands which risk each instrument addresses can negotiate the instrument down by removing the risk, which is a far better argument than objecting to the structure in principle.

Diligence in this sector goes places it does not go elsewhere, and unprepared sellers lose both time and leverage.

Patient records are special category data under the GDPR, and their handling on a change of ownership is a legal question, not an IT one. Buyers will want the lawful basis documented, the retention policy evidenced, and any processor arrangements in order.

Clinical governance is examined directly: incident and complaint logs, audit records, inspection history, protocols and their version control, and evidence that adverse events were investigated. A clinic with a thin governance file is not merely untidy; it is unquantifiable, and buyers price the unknown pessimistically.

Liability follows the work for years. Buyers examine the professional indemnity position, including whether cover is claims-made or occurrence-based and whether run-off cover is in place for historic activity, since the difference determines who carries claims arising after completion from treatment given before it.

Billing and coding history matters where any income comes from insurers or public payers. Historic coding practices are a classic source of post-completion claims, and this is precisely what the regulatory escrow is there for.

Clinician-owned groups are frequently the only buyers who can complete without structural gymnastics, and in restricted jurisdictions they are the natural first port of call. They understand the clinical risk and often pay fairly for a well-run practice.

Hospital groups and integrated providers buy for referral capture, capacity or specialty coverage, and in jurisdictions such as Germany a hospital may be the permitted route through which outside capital participates at all.

Financial investors remain active, but in this sector they arrive with a structure already designed and a legal opinion already obtained. Their interest concentrates on specialties with predictable demand, limited reimbursement exposure and scope for standardised operations.

Insurers and vertically integrated payers appear in some markets, buying clinical capacity to control cost and pathway.

Establishing which of these can lawfully and realistically complete, before any materials are written, is where Conclave Partners spends the first weeks of a clinic mandate.

Get the regulatory position in writing. For each authorisation, contract and panel place: what happens on a change of ownership, whether a share sale is treated differently from an asset sale, and how long any approval takes.

Reduce dependence on any single clinician. Introduce multi-clinician cover for each service line, move referral relationships onto clinic contact points, and let a full year of activity data show the change.

Formalise the medical team. Written agreements with notice periods and enforceable restrictive covenants, for employed and self-employed clinicians alike.

Rebuild the activity analysis: revenue and margin by service line, by clinician and by referral source, for three years, reconciled to the accounts.

Put the governance file in order: incidents, complaints, audits, inspection reports, protocols, training records.

Confirm the insurance position, including run-off cover for the historic period, and obtain written confirmation rather than assuming.

Document the data protection position for patient records, including what will happen to them on a transfer.

Normalise the accounts honestly, including a market salary for any owner-clinician's own clinical work — the same principle that applies in dentistry and professional services, and for the same reason. Adjustments a buyer can verify are accepted; adjustments supported only by the owner's word cause the buyer to discount the whole earnings figure. Sellers who ask Conclave Partners where to begin are pointed at the regulatory answer and the activity-by-clinician analysis, because those two documents determine who can buy and at what price.

A prepared clinic typically takes nine to twelve months from launch to completion — longer than most sectors of similar size, because regulatory approvals and payer consents sit on the critical path and are not within the parties' control.

Expect diligence to run in parallel streams: financial, clinical and regulatory, often with different advisers, and expect the clinical stream to ask questions the finance team cannot answer.

Confidentiality is unusually sensitive. Clinicians are mobile and actively recruited, referral sources dislike uncertainty, and patients notice. A leak damages the referral base, which is the asset being sold.

Not in several European jurisdictions. German law restricts who may found a medical care centre under Section 95(1a) SGB V to authorised physicians, hospitals and certain non-profit bodies, and the Court of Justice confirmed in December 2024 the prohibition on third-party participation in liberal-profession practices, so financial investors can participate only indirectly. Comparable restrictions exist elsewhere. The buyer list must be built on legal eligibility first.

It depends on the permission and on the deal structure. Facility authorisations are typically tied to an operator and premises and respond to a change of control; individual practitioner registrations are separate and personal; payer contracts and panel places have their own procedures and are sometimes not transferable. A share sale often preserves continuity where an asset sale would not.

It works the way key person risk works everywhere: through the multiple and, more visibly, through the structure. Expect a larger rollover, a longer earn-out and payment tied to retention of activity. A clinic where several clinicians can deliver each service line, and where referrals come to the institution, avoids most of it.

A retained portion of the price held against the possibility that an authorisation, a payer contract or a historic billing practice proves defective after completion. It is common in healthcare transactions because those risks are real and difficult to quantify in advance. Clean documentation reduces both its size and its duration.

Usually not, for the same reason as in other clinical settings: most buyers do not want to fund real estate, and retaining it with a market-rent lease widens the buyer pool. The lease must be properly documented, because an artificial rent distorts the earnings the buyer is underwriting.

Roughly nine to twelve months from launch to completion for a prepared business, with regulatory approvals and payer consents the usual reason it takes longer than comparable sectors. Preparation before launch — spreading clinical dependence and assembling the governance and regulatory files — needs a further twelve months to show in the data.

Ildar Zakirov — Conclave Partners ildar@conclavepartners.com

Sergi Kosiakof — Conclave Partners sergi@conclavepartners.com